Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinsonian Disorders | 10 | 2023 | 217 | 5.030 |
Why?
|
| Stroke | 20 | 2023 | 293 | 4.170 |
Why?
|
| Brain | 16 | 2023 | 1687 | 3.610 |
Why?
|
| Alzheimer Disease | 13 | 2023 | 1943 | 3.440 |
Why?
|
| Cognitive Dysfunction | 9 | 2023 | 938 | 2.840 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2022 | 51 | 2.410 |
Why?
|
| Cerebrovascular Disorders | 4 | 2023 | 132 | 1.950 |
Why?
|
| Aged, 80 and over | 28 | 2023 | 4851 | 1.820 |
Why?
|
| Aged | 43 | 2023 | 9447 | 1.820 |
Why?
|
| Brain Ischemia | 6 | 2020 | 71 | 1.690 |
Why?
|
| Female | 56 | 2023 | 16211 | 1.620 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 63 | 1.610 |
Why?
|
| Male | 54 | 2023 | 15637 | 1.560 |
Why?
|
| Dementia | 4 | 2023 | 521 | 1.470 |
Why?
|
| Humans | 69 | 2023 | 29361 | 1.440 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 227 | 1.380 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 71 | 1.200 |
Why?
|
| Atherosclerosis | 3 | 2023 | 72 | 1.150 |
Why?
|
| Hypertension | 8 | 2023 | 266 | 1.150 |
Why?
|
| Risk Factors | 24 | 2023 | 2446 | 1.130 |
Why?
|
| Neuropsychological Tests | 6 | 2023 | 1251 | 1.120 |
Why?
|
| Dementia, Vascular | 2 | 2016 | 41 | 1.120 |
Why?
|
| Aging | 11 | 2023 | 1594 | 1.110 |
Why?
|
| tau Proteins | 4 | 2023 | 202 | 1.080 |
Why?
|
| Incidence | 15 | 2022 | 756 | 1.060 |
Why?
|
| Disease Progression | 5 | 2021 | 788 | 1.040 |
Why?
|
| Independent Living | 4 | 2023 | 281 | 1.010 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2023 | 104 | 1.000 |
Why?
|
| Stroke Rehabilitation | 2 | 2019 | 11 | 0.990 |
Why?
|
| Limbic Encephalitis | 1 | 2023 | 10 | 0.930 |
Why?
|
| Cardiovascular Diseases | 10 | 2018 | 401 | 0.930 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 294 | 0.920 |
Why?
|
| Motor Disorders | 1 | 2023 | 22 | 0.910 |
Why?
|
| Disabled Persons | 2 | 2023 | 127 | 0.880 |
Why?
|
| Iran | 18 | 2021 | 36 | 0.850 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1442 | 0.840 |
Why?
|
| Executive Function | 2 | 2015 | 121 | 0.830 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 152 | 0.780 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 17 | 0.760 |
Why?
|
| Exercise | 4 | 2023 | 468 | 0.760 |
Why?
|
| Health Status | 2 | 2021 | 227 | 0.740 |
Why?
|
| Mobility Limitation | 1 | 2021 | 97 | 0.730 |
Why?
|
| Cerebral Hemorrhage | 7 | 2023 | 129 | 0.730 |
Why?
|
| White Matter | 1 | 2021 | 148 | 0.720 |
Why?
|
| Child Development | 1 | 2020 | 71 | 0.720 |
Why?
|
| Vision, Ocular | 1 | 2019 | 3 | 0.720 |
Why?
|
| Eyeglasses | 1 | 2019 | 3 | 0.710 |
Why?
|
| Beta Rhythm | 1 | 2019 | 4 | 0.710 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 115 | 0.710 |
Why?
|
| Mental Health | 1 | 2021 | 105 | 0.710 |
Why?
|
| Agnosia | 1 | 2019 | 10 | 0.710 |
Why?
|
| Visual Perception | 1 | 2019 | 50 | 0.690 |
Why?
|
| Blood Pressure | 2 | 2020 | 238 | 0.690 |
Why?
|
| Cohort Studies | 14 | 2022 | 1939 | 0.690 |
Why?
|
| Brain Infarction | 1 | 2020 | 74 | 0.690 |
Why?
|
| Gait | 1 | 2023 | 404 | 0.680 |
Why?
|
| Motor Activity | 3 | 2019 | 369 | 0.660 |
Why?
|
| Cognition | 4 | 2023 | 1279 | 0.650 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2017 | 8 | 0.610 |
Why?
|
| Sex Characteristics | 1 | 2018 | 132 | 0.610 |
Why?
|
| Upper Extremity | 1 | 2017 | 49 | 0.600 |
Why?
|
| Age Factors | 7 | 2021 | 845 | 0.570 |
Why?
|
| Middle Aged | 29 | 2023 | 9823 | 0.550 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2015 | 36 | 0.550 |
Why?
|
| Autopsy | 4 | 2021 | 335 | 0.540 |
Why?
|
| Aspirin | 1 | 2015 | 83 | 0.510 |
Why?
|
| Triglycerides | 3 | 2022 | 41 | 0.510 |
Why?
|
| Case-Control Studies | 11 | 2023 | 638 | 0.460 |
Why?
|
| Metabolic Syndrome | 4 | 2018 | 66 | 0.450 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 58 | 0.450 |
Why?
|
| Parkinson Disease | 4 | 2023 | 1164 | 0.410 |
Why?
|
| Canada | 4 | 2015 | 56 | 0.380 |
Why?
|
| Obesity | 4 | 2019 | 290 | 0.360 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 255 | 0.350 |
Why?
|
| Adult | 18 | 2023 | 8604 | 0.350 |
Why?
|
| Prospective Studies | 9 | 2023 | 1812 | 0.340 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 1829 | 0.340 |
Why?
|
| Waist Circumference | 4 | 2019 | 36 | 0.330 |
Why?
|
| Time Factors | 4 | 2019 | 1618 | 0.330 |
Why?
|
| Cognition Disorders | 3 | 2016 | 1010 | 0.320 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 441 | 0.300 |
Why?
|
| Recovery of Function | 2 | 2019 | 290 | 0.290 |
Why?
|
| Disability Evaluation | 2 | 2019 | 327 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2021 | 3476 | 0.280 |
Why?
|
| Language | 1 | 2006 | 78 | 0.270 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 502 | 0.270 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 340 | 0.260 |
Why?
|
| Neurofibrillary Tangles | 2 | 2023 | 181 | 0.260 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 965 | 0.260 |
Why?
|
| Waist-Hip Ratio | 5 | 2019 | 16 | 0.260 |
Why?
|
| Hospitalization | 1 | 2007 | 317 | 0.250 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1184 | 0.250 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2023 | 20 | 0.240 |
Why?
|
| Risk Assessment | 4 | 2021 | 678 | 0.230 |
Why?
|
| Binge Drinking | 1 | 2023 | 10 | 0.230 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 33 | 0.220 |
Why?
|
| RNA | 1 | 2023 | 39 | 0.220 |
Why?
|
| Cerebrum | 1 | 2023 | 9 | 0.220 |
Why?
|
| Smoking | 3 | 2020 | 194 | 0.220 |
Why?
|
| Opium | 1 | 2022 | 1 | 0.220 |
Why?
|
| Hand Strength | 1 | 2023 | 59 | 0.220 |
Why?
|
| Cholesterol | 1 | 2022 | 49 | 0.220 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 52 | 0.220 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 1 | 0.210 |
Why?
|
| Spinal Cord | 1 | 2022 | 103 | 0.210 |
Why?
|
| Motor Cortex | 1 | 2021 | 17 | 0.210 |
Why?
|
| Migraine Disorders | 1 | 2021 | 14 | 0.210 |
Why?
|
| Ontario | 1 | 2021 | 17 | 0.200 |
Why?
|
| Life Style | 2 | 2020 | 211 | 0.200 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 137 | 0.200 |
Why?
|
| Potassium | 1 | 2021 | 67 | 0.200 |
Why?
|
| Sodium | 1 | 2021 | 76 | 0.190 |
Why?
|
| Nerve Block | 1 | 2021 | 62 | 0.190 |
Why?
|
| Walking | 1 | 2023 | 252 | 0.190 |
Why?
|
| Peptides | 1 | 2021 | 95 | 0.190 |
Why?
|
| Sex Factors | 2 | 2020 | 496 | 0.190 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 216 | 0.180 |
Why?
|
| Movement Disorders | 1 | 2021 | 141 | 0.180 |
Why?
|
| Biomarkers | 2 | 2020 | 692 | 0.180 |
Why?
|
| Residence Characteristics | 2 | 2012 | 217 | 0.180 |
Why?
|
| Linear Models | 1 | 2020 | 254 | 0.170 |
Why?
|
| Functional Laterality | 1 | 2019 | 91 | 0.170 |
Why?
|
| Noncommunicable Diseases | 1 | 2018 | 2 | 0.170 |
Why?
|
| Heredity | 1 | 2018 | 6 | 0.170 |
Why?
|
| Apolipoproteins E | 1 | 2020 | 230 | 0.170 |
Why?
|
| Pedigree | 1 | 2018 | 77 | 0.170 |
Why?
|
| Depression | 1 | 2023 | 466 | 0.170 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2018 | 1 | 0.170 |
Why?
|
| Glycogen | 1 | 2018 | 12 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 364 | 0.160 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 145 | 0.160 |
Why?
|
| ROC Curve | 4 | 2022 | 138 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2019 | 394 | 0.160 |
Why?
|
| Milk | 1 | 2017 | 9 | 0.160 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 14 | 0.160 |
Why?
|
| CADASIL | 1 | 2017 | 1 | 0.160 |
Why?
|
| Research Design | 1 | 2018 | 212 | 0.150 |
Why?
|
| Chicago | 1 | 2020 | 865 | 0.150 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 138 | 0.150 |
Why?
|
| Genotype | 1 | 2018 | 405 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 132 | 0.150 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 5 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2017 | 227 | 0.150 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2016 | 10 | 0.150 |
Why?
|
| Menopause | 1 | 2018 | 134 | 0.150 |
Why?
|
| Vasodilation | 1 | 2016 | 19 | 0.150 |
Why?
|
| Mutation | 1 | 2018 | 383 | 0.140 |
Why?
|
| Child | 1 | 2020 | 1345 | 0.140 |
Why?
|
| Neuropathology | 1 | 2016 | 79 | 0.140 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 52 | 0.140 |
Why?
|
| Tropanes | 1 | 2015 | 4 | 0.140 |
Why?
|
| Organotechnetium Compounds | 1 | 2015 | 8 | 0.140 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 54 | 0.140 |
Why?
|
| Methamphetamine | 1 | 2016 | 48 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 521 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 13 | 0.140 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 27 | 0.140 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 50 | 0.130 |
Why?
|
| Prediabetic State | 1 | 2014 | 4 | 0.130 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 75 | 0.130 |
Why?
|
| Incidental Findings | 1 | 2014 | 16 | 0.120 |
Why?
|
| Heart Rate | 1 | 2014 | 142 | 0.120 |
Why?
|
| Body Mass Index | 3 | 2023 | 427 | 0.110 |
Why?
|
| Interviews as Topic | 2 | 2019 | 130 | 0.110 |
Why?
|
| Memory | 1 | 2015 | 318 | 0.110 |
Why?
|
| Rural Population | 1 | 2012 | 23 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 200 | 0.100 |
Why?
|
| Urban Population | 1 | 2012 | 143 | 0.100 |
Why?
|
| Quality of Life | 1 | 2016 | 664 | 0.100 |
Why?
|
| Phenotype | 2 | 2023 | 357 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 78 | 0.090 |
Why?
|
| Logistic Models | 1 | 2010 | 407 | 0.080 |
Why?
|
| Efferent Pathways | 1 | 2008 | 1 | 0.080 |
Why?
|
| Neural Conduction | 1 | 2008 | 8 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 788 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3273 | 0.080 |
Why?
|
| Age Distribution | 1 | 2007 | 94 | 0.080 |
Why?
|
| Skin | 1 | 2008 | 117 | 0.080 |
Why?
|
| Action Potentials | 1 | 2008 | 137 | 0.080 |
Why?
|
| Middle East | 2 | 2017 | 5 | 0.080 |
Why?
|
| Comorbidity | 2 | 2021 | 497 | 0.070 |
Why?
|
| Developing Countries | 2 | 2018 | 22 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2017 | 64 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 1113 | 0.070 |
Why?
|
| Europe | 2 | 2016 | 81 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 206 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2017 | 285 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 324 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 840 | 0.060 |
Why?
|
| Angina, Unstable | 2 | 2014 | 11 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2014 | 20 | 0.060 |
Why?
|
| Prevalence | 2 | 2016 | 491 | 0.060 |
Why?
|
| Infarction | 1 | 2023 | 23 | 0.060 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 5 | 0.060 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 5 | 0.060 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 16 | 0.060 |
Why?
|
| Proteome | 1 | 2023 | 39 | 0.060 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 172 | 0.050 |
Why?
|
| Health Surveys | 2 | 2013 | 96 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2021 | 16 | 0.050 |
Why?
|
| Triamcinolone | 1 | 2021 | 5 | 0.050 |
Why?
|
| Lewy Bodies | 1 | 2023 | 195 | 0.050 |
Why?
|
| Lidocaine | 1 | 2021 | 40 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 38 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 43 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 1 | 0.050 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 8 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 126 | 0.050 |
Why?
|
| Young Adult | 2 | 2018 | 1935 | 0.050 |
Why?
|
| Causality | 1 | 2021 | 53 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 59 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2021 | 321 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2022 | 246 | 0.050 |
Why?
|
| Sleep | 1 | 2023 | 313 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2019 | 29 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 6 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 20 | 0.040 |
Why?
|
| Anthropometry | 1 | 2019 | 37 | 0.040 |
Why?
|
| Adiposity | 1 | 2019 | 47 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 18 | 0.040 |
Why?
|
| Physical Examination | 1 | 2019 | 117 | 0.040 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2018 | 1 | 0.040 |
Why?
|
| Developed Countries | 1 | 2018 | 4 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 74 | 0.040 |
Why?
|
| Mediterranean Region | 1 | 2017 | 3 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 43 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 108 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 298 | 0.040 |
Why?
|
| Microvessels | 1 | 2017 | 16 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 96 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 101 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2018 | 79 | 0.040 |
Why?
|
| Nitroglycerin | 1 | 2016 | 4 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2016 | 8 | 0.040 |
Why?
|
| Overweight | 1 | 2017 | 65 | 0.040 |
Why?
|
| Apolipoproteins B | 1 | 2016 | 3 | 0.040 |
Why?
|
| Asia | 1 | 2016 | 9 | 0.040 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 24 | 0.040 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 5 | 0.040 |
Why?
|
| Africa | 1 | 2016 | 10 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2017 | 298 | 0.040 |
Why?
|
| Australia | 1 | 2016 | 44 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 32 | 0.040 |
Why?
|
| International Cooperation | 1 | 2016 | 32 | 0.040 |
Why?
|
| China | 1 | 2016 | 59 | 0.040 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 22 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 324 | 0.040 |
Why?
|
| Risk | 1 | 2016 | 217 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 77 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 33 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 70 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 100 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 218 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 349 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 159 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 329 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 389 | 0.030 |
Why?
|
| United States | 1 | 2021 | 2332 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 174 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 183 | 0.030 |
Why?
|
| Rural Health | 1 | 2013 | 8 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 23 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 18 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 96 | 0.030 |
Why?
|
| Adolescent | 1 | 2018 | 2280 | 0.030 |
Why?
|
| Public Health | 1 | 2012 | 61 | 0.030 |
Why?
|
| Reference Values | 1 | 2012 | 227 | 0.030 |
Why?
|
| Survival Rate | 1 | 2012 | 349 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 132 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 219 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 4577 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 129 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 83 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 45 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 226 | 0.020 |
Why?
|